Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer.

about

Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer.

Item

http://www.wikidata.org/entity/Q55505567

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Emerging evidence of the molec ...... etastasis from gastric cancer.

@en

Emerging evidence of the molec ...... etastasis from gastric cancer.

@nl

type

Item

label

Emerging evidence of the molec ...... etastasis from gastric cancer.

@en

Emerging evidence of the molec ...... etastasis from gastric cancer.

@nl

prefLabel

Emerging evidence of the molec ...... etastasis from gastric cancer.

@en

Emerging evidence of the molec ...... etastasis from gastric cancer.

@nl

P1476

Emerging evidence of the molec ...... metastasis from gastric cancer

@en

P2093

Dai Shimizu

http://www.w3.org/2001/XMLSchema#string

Mitsuro Kanda

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Kodera

http://www.w3.org/2001/XMLSchema#string

P2860

Nucleophosmin (NPM1/B23) interacts with activating transcription factor 5 (ATF5) protein and promotes proteasome- and caspase-dependent ATF5 degradation in hepatocellular carcinoma cells

Initial genome sequencing and analysis of multiple myeloma

Nanotubes, exosomes, and nucleic acid-binding peptides provide novel mechanisms of intercellular communication in eukaryotic cells: implications in health and disease

Molecular mechanisms of peritoneal dissemination in gastric cancer

Engineering therapeutic antibodies targeting G-protein-coupled receptors

Classification, functions, and clinical relevance of extracellular vesicles

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Epithelial-mesenchymal transitions in tumour progression

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

P304

124-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4251/WJGO.V10.I6.124

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29988904

http://www.w3.org/2001/XMLSchema#string

P932

6033711

http://www.w3.org/2001/XMLSchema#string